Tebentafusp: a first-in-class treatment for metastatic uveal melanoma

被引：28
|
作者：
Howlett, Sarah [1 ]
Carter, Thomas J. [1 ]
Shaw, Heather M. [1 ,2 ]
Nathan, Paul D. [3 ]
机构：
[1] Mt Vernon Canc Ctr, Middlesex, England
[2] Univ Coll London Hosp, London, England
[3] Mt Vernon Canc Ctr, Rickmansworth Rd, Middlesex HA6 2RN, England
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2023年 / 15卷
关键词：
gp100; ImmTAC; metastatic; tebentafusp; uveal melanoma; PHASE-II TRIAL; PD-L1; EXPRESSION; PATIENTS PTS; OPEN-LABEL; MULTICENTER; IPILIMUMAB; SURVIVAL; NIVOLUMAB; EFFICACY; GEMCITABINE;
D O I：
10.1177/17588359231160140
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Tebentafusp is a first-in-class immunotherapy agent that comprises an engineered T-cell receptor targeting a gp100 epitope presented by human leukocyte antigen-A*02:01 cells, fused to an anti-CD3 single-chain variable fragment. Tebentafusp is both the first bispecific T-cell engager to show efficacy in the treatment of advanced solid cancer and the first anti-cancer treatment to demonstrate an overall survival benefit in patients with uveal melanoma (UM). This review article will focus on the clinical development of tebentafusp, the mechanism of action and resultant evolution of the management of advanced UM.
引用
收藏
页数：12
相关论文
共 50 条
  • [1] Tebentafusp for the treatment of metastatic uveal melanoma
    Schank, Timo E.
    Hassel, Jessica C.
    FUTURE ONCOLOGY, 2022, 18 (11) : 1303 - 1311
  • [2] Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma
    Wang, Zhijian
    Xie, Yuhao
    Wang, Jing-Quan
    Cheng, Yuanhui
    Fleishman, Joshua
    Chen, Zhe-Sheng
    Chen, Yun
    DRUGS OF TODAY, 2023, 59 (03) : 179 - 193
  • [3] Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma
    Damato, Bertil E.
    Dukes, Joseph
    Goodall, Howard
    Carvajal, Richard D.
    CANCERS, 2019, 11 (07)
  • [4] Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations
    Montazeri, Kamaneh
    Pattanayak, Vikram
    Sullivan, Ryan J.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2023, 17 : 333 - 339
  • [5] Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
    Nathan, Paul
    Hassel, Jessica C.
    Rutkowski, Piotr
    Baurain, Jean-Francois
    Butler, Marcus O.
    Schlaak, Max
    Sullivan, Ryan J.
    Ochsenreither, Sebastian
    Dummer, Reinhard
    Kirkwood, John M.
    Joshua, Anthony M.
    Sacco, Joseph J.
    Shoushtari, Alexander N.
    Orloff, Marlana
    Piulats, Josep M.
    Milhem, Mohammed
    Salama, April K. S.
    Curti, Brendan
    Demidov, Lev
    Gastaud, Lauris
    Mauch, Cornelia
    Yushak, Melinda
    Carvajal, Richard D.
    Hamid, Omid
    Abdullah, Shaad E.
    Holland, Chris
    Goodall, Howard
    Piperno-Neumann, Sophie
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (13): : 1196 - 1206
  • [6] Tebentafusp for uveal melanoma
    Killock, David
    NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (12) : 747 - 747
  • [7] Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma
    Schlaak, M.
    Dummer, R.
    Kirkwood, J. M.
    Joshua, A.
    Milhem, M.
    Gastaud, L.
    Mauch, C.
    Yushak, M. L.
    Lockwood, S.
    Hayes, C.
    Shoushtari, A. N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S923 - S923
  • [8] Tebentafusp for uveal melanoma
    David Killock
    Nature Reviews Clinical Oncology, 2021, 18 : 747 - 747
  • [9] Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma
    Al Balushi, Khalid
    Al Hadhrami, Abdulrahman
    Al Balushi, Hamdan
    Al Lawati, Abdullah
    Das, Srijit
    CURRENT DRUG TARGETS, 2024, 25 (03) : 149 - 157
  • [10] Tebentafusp as a treatment option for metastatic uveal melanoma: when does a patient no longer benefit?
    Scharnowski, E.
    Klespe, K. C.
    Glauner, A.
    Haeger, C.
    Glaser, A. C.
    Kreuzberg, N.
    Mauch, C.
    Franklin, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 63 - 64
12345